Andra AP fonden acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 27,900 shares of the company’s stock, valued at approximately $6,238,000.
A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc lifted its stake in IDEXX Laboratories by 0.3% in the 3rd quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock valued at $2,226,581,000 after purchasing an additional 23,970 shares during the last quarter. BlackRock Inc. lifted its stake in IDEXX Laboratories by 4.6% in the 4th quarter. BlackRock Inc. now owns 6,549,022 shares of the company’s stock valued at $1,218,251,000 after purchasing an additional 289,208 shares during the last quarter. Fundsmith LLP lifted its stake in IDEXX Laboratories by 0.8% in the 1st quarter. Fundsmith LLP now owns 4,467,341 shares of the company’s stock valued at $998,897,000 after purchasing an additional 35,049 shares during the last quarter. Geode Capital Management LLC lifted its stake in IDEXX Laboratories by 7.6% in the 4th quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock valued at $215,959,000 after purchasing an additional 81,641 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in IDEXX Laboratories by 36.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,076,895 shares of the company’s stock valued at $240,793,000 after purchasing an additional 289,063 shares during the last quarter. 87.76% of the stock is owned by institutional investors and hedge funds.
In other news, insider Giovani Twigge sold 2,600 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $250.14, for a total transaction of $650,364.00. Following the completion of the transaction, the insider now owns 12,595 shares of the company’s stock, valued at $3,150,513.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Brian P. Mckeon sold 7,504 shares of the firm’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $247.87, for a total transaction of $1,860,016.48. The disclosure for this sale can be found here. Insiders have sold 50,721 shares of company stock valued at $12,554,774 in the last ninety days. Insiders own 2.70% of the company’s stock.
IDXX stock opened at $267.16 on Friday. The firm has a market cap of $22.80 billion, a PE ratio of 62.71 and a beta of 0.84. IDEXX Laboratories, Inc. has a 52-week low of $176.11 and a 52-week high of $271.34. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.13. The firm had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.01 earnings per share. On average, research analysts predict that IDEXX Laboratories, Inc. will post 4.82 EPS for the current year.
Several research firms have recently issued reports on IDXX. Canaccord Genuity dropped their price target on shares of IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research note on Tuesday, March 26th. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd. Guggenheim began coverage on shares of IDEXX Laboratories in a research note on Thursday, May 23rd. They set a “buy” rating and a $276.00 price target for the company. Finally, BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, April 30th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $256.71.
ILLEGAL ACTIVITY NOTICE: “Andra AP fonden Acquires Shares of 27,900 IDEXX Laboratories, Inc. (NASDAQ:IDXX)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2019/06/14/andra-ap-fonden-acquires-shares-of-27900-idexx-laboratories-inc-nasdaqidxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Story: Stock Symbol
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.